Drug Trial Radar · NCT04384367
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,068
Actual
Start
Dec 30, 2022
Primary completion
Oct 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Conditions
- Migraine
Interventions
Rizatriptan 10 mg + Naproxen 550mgDrug
oral - single dose
Maxalt 10Mg TabletDrug
oral - single dose
Flanax 550mgDrug
oral - single dose
Placebo oral tabletDrug
oral - single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-hour pain-freeTime frame: 11 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eurofarma Laboratorios S.A
São Paulo, São Paulo, Brazil
CEPIC
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.